Comparative Pharmacology
Head-to-head clinical analysis: CEFTAROLINE FOSAMIL versus CEPHRADINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTAROLINE FOSAMIL versus CEPHRADINE.
CEFTAROLINE FOSAMIL vs CEPHRADINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftaroline fosamil is a prodrug that is converted to the active metabolite ceftaroline. Ceftaroline inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), including PBP2a in MRSA and PBP2x in Streptococcus pneumoniae, thereby preventing cross-linking of peptidoglycan.
Cephradine is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
600 mg IV every 12 hours infused over 1 hour
250-500 mg orally every 6 hours; 500 mg to 1 g intramuscularly or intravenously every 6 hours. Maximum: 4 g/day.
None Documented
None Documented
Terminal elimination half-life is approximately 2.6 hours in patients with normal renal function. This supports twice-daily dosing in most infections.
Terminal elimination half-life 0.5–1.5 hours (normal renal function); prolonged to 6–15 hours in severe renal impairment (CrCl <10 mL/min).
Renal excretion of unchanged ceftaroline accounts for approximately 88% of the administered dose. Biliary/fecal elimination is minimal (<6%).
Primarily renal (≥90% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal (<10%).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic